Our findings suggest that selective inhibition of CDK6 expression, rather than the use of CDK4/6 dual inhibitors such as palbociclib, during RA treatment, may preclude the adverse effects of myelosuppression and offer potential therapeutic benefits in RA. The gene discussed is CDK4; the disease is rheumatoid arthritis.